Hydroxychloroquine
- Generic Name
- Hydroxychloroquine
- Brand Names
- Plaquenil, Sovuna
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3O
- CAS Number
- 118-42-3
- Unique Ingredient Identifier
- 4QWG6N8QKH
- Background
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of quinacrine with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2.
The FDA emergency use authorization for hydroxychloroquine and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.
Hydroxychloroquine was granted FDA approval on 18 April 1955.
A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.
- Indication
Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.
- Associated Conditions
- Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum
- Associated Therapies
- -
Hydroxychloroquine in Blocking Autophagy in Patients With Prostate Cancer Undergoing Surgery or Active Surveillance
- Conditions
- Interventions
- First Posted Date
- 2015-04-20
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 4
- Registration Number
- NCT02421575
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Hydroxychloroquine in Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Hormonal Therapy
- Conditions
- Interventions
- First Posted Date
- 2015-04-13
- Last Posted Date
- 2017-09-27
- Lead Sponsor
- Western Regional Medical Center
- Target Recruit Count
- 3
- Registration Number
- NCT02414776
- Locations
- 🇺🇸
Western Regional Medical Center, Inc., Goodyear, Arizona, United States
Treatments Against RA and Effect on FDG-PET/CT
- Conditions
- Interventions
- First Posted Date
- 2015-02-27
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 159
- Registration Number
- NCT02374021
- Locations
- 🇺🇸
IRIS Research and Development, Plantation, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study
- First Posted Date
- 2015-01-30
- Last Posted Date
- 2015-12-17
- Lead Sponsor
- LLiu
- Target Recruit Count
- 20
- Registration Number
- NCT02351752
- Locations
- 🇨🇳
Peking University First Hospital, BeiJing, Beijing, China
Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-12-12
- Last Posted Date
- 2024-01-05
- Target Recruit Count
- 42
- Registration Number
- NCT02316340
- Locations
- 🇺🇸
Cancer Therapy and Research Center University of Texas Health Science Center San Antonio, San Antonio, Texas, United States
Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2014-11-27
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Charles Drew University of Medicine and Science
- Target Recruit Count
- 22
- Registration Number
- NCT02303405
- Locations
- 🇺🇸
Charles Drew University of Medicine and Science, Los Angeles, California, United States
The Effect of Plaquenil on Serum Inflammatory Markers and Goiter in Euthyroid Young Women With Hashimoto's Thyroiditis
- First Posted Date
- 2014-04-30
- Last Posted Date
- 2014-04-30
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT02126683
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Rediscovering Hydroxychloroquine as a Novel Insulin Sensitizer
- First Posted Date
- 2014-04-28
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 34
- Registration Number
- NCT02124681
- Locations
- 🇺🇸
UPMC Montefiore Hospital, Pittsburgh, Pennsylvania, United States
To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis
- First Posted Date
- 2014-02-07
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 217
- Registration Number
- NCT02057250
- Locations
- 🇨🇱
Investigational Site Number 152050, Santiago, Chile
🇨🇱Investigational Site Number 152007, Viña Del Mar, Chile
🇲🇽Investigational Site Number 484005, Monterrey, Mexico
Metabolic Effects of Hydroxychloroquine
- Conditions
- Interventions
- First Posted Date
- 2014-01-01
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 21
- Registration Number
- NCT02026232
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.